联合临床风险分层和粪便免疫化学检测有助于识别具有早期结肠镜检查高优先级的人群。
A combination of clinical risk stratification and fecal immunochemical test is useful for identifying persons with high priority of early colonoscopy.
机构信息
Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Republic of Korea.
出版信息
Dig Liver Dis. 2018 Mar;50(3):254-259. doi: 10.1016/j.dld.2017.11.002. Epub 2017 Nov 15.
BACKGROUND
We aimed to develop a combination screening strategy for advanced colorectal neoplasia based on the Asia-Pacific Colorectal Screening score and fecal immunochemical test results.
METHODS
We reviewed the records of participants who had undergone a colonoscopy and fecal immunochemical test as part of a comprehensive health screening program. The prevalence of advanced colorectal neoplasia in participants 40-49 years old was analyzed according to Asia-Pacific Colorectal Screening scores and fecal immunochemical test results.
RESULTS
We analyzed the data of 9205 participants 40-49 years old and 3215 participants ≥50 years old. The prevalence of advanced colorectal neoplasia in participants 40-49 years old was 1.0%, 2.1%, 7.1%, and 13.4% in the "fecal immunochemical test (-) & Asia-Pacific Colorectal Screening<2," "fecal immunochemical test (-) & Asia-Pacific Colorectal Screening≥2," "fecal immunochemical test (+) & Asia-Pacific Colorectal Screening<2," and "fecal immunochemical test (+) & Asia-Pacific Colorectal Screening≥2" subgroups, respectively. The prevalence of advanced colorectal neoplasia in "fecal immunochemical test (+) & Asia-Pacific Colorectal Screening≥2" subgroup was higher than in participants ≥50 years old with Asia-Pacific Colorectal Screening≥4 (13.4% vs. 5.8%, P<0.001).
CONCLUSIONS
Fecal immunochemical test-positive individuals 40-49 years old with an Asia-Pacific Colorectal Screening≥2 have a higher risk of advanced colorectal neoplasia than individuals ≥50 years old with an Asia-Pacific Colorectal Screening≥4.
背景
本研究旨在基于亚太结直肠筛查评分和粪便免疫化学检测结果制定用于筛查进展期结直肠肿瘤的联合筛查策略。
方法
我们对参加综合健康筛查计划并接受结肠镜检查和粪便免疫化学检测的参与者的记录进行了回顾。根据亚太结直肠筛查评分和粪便免疫化学检测结果分析 40-49 岁参与者中进展期结直肠肿瘤的患病率。
结果
我们分析了 9205 名 40-49 岁和 3215 名≥50 岁参与者的数据。在 40-49 岁参与者中，粪便免疫化学检测（-）和亚太结直肠筛查评分<2、粪便免疫化学检测（-）和亚太结直肠筛查评分≥2、粪便免疫化学检测（+）和亚太结直肠筛查评分<2、粪便免疫化学检测（+）和亚太结直肠筛查评分≥2 亚组中，进展期结直肠肿瘤的患病率分别为 1.0%、2.1%、7.1%和 13.4%。粪便免疫化学检测（+）和亚太结直肠筛查评分≥2 亚组中进展期结直肠肿瘤的患病率高于亚太结直肠筛查评分≥4 的≥50 岁参与者（13.4% vs. 5.8%，P<0.001）。
结论
亚太结直肠筛查评分≥2 且粪便免疫化学检测阳性的 40-49 岁个体发生进展期结直肠肿瘤的风险高于亚太结直肠筛查评分≥4 的≥50 岁个体。
Zotero 插件